Motley Fool Australia
  •  

    Notifications

    Scott

    Wondering where you should invest $1,000 right now?

    Scott Phillips just released his 5 best stocks to buy right now and you could grab the names of these stocks instantly!

    Learn More
  • Log Out
  • Menu
  1. Stocks
    2. /
  2. Anatara Lifesciences Ltd (ASX: ANR)
    3. /

Anatara Lifesciences Ltd (ASX: ANR) Share Price and News

Price

$0.007

Movement

0.001 (-12.5%)

As at 13 Mar - Closed (20 mins delayed)

52 Week Range

$0.008 - $0.073

 
1 Year Return

-82.05%

Anatara Lifesciences Ltd Chart and Price Data

2025
2025
2025
2025
$0.00
$0.05
$0.10
$0.00
$0.05
$0.10
$0.00
$0.05
$0.10
$0.00
$0.05
$0.10

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.71 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 213.38 million
Earnings per share -0.010
Dividend per share N/A
Year To Date Return -82.98%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-82.98%

Shares Outstanding

213.38 million

Earnings per share

-0.010

Share Price

$0.007

Day Change

0.001 (-12.5%)

52 Week Range

$0.008 - $0.073

Yesterday's Close

$0.008

Today's Open

$0.008

Days Range

$0.007 - $0.008

Volume

1,996,397

Avg. Volume (1 month)

2,496,945

Turnover

$15,934

As at 13 Mar - Closed

  • Should you invest $1,000 in Ebr Systems, Inc. right now?

    Before you buy Ebr Systems, Inc. shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Ebr Systems, Inc. wasn't one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys...

    See The 5 Stocks *Returns as of 6 March 2025

    • Anatara Lifesciences Ltd (ASX: ANR)
    Latest News

    investor looking excited at rising fortescue share price on laptop
    Share Market News

    Why the Anatara (ASX:ANR) share price is rocketing 19% today

    | Aaron Teboneras

    The Anatara Lifesciences Ltd (ASX: ANR) share price is one of the best performers on the ASX today. Here's what…

    Read more »

    a woman
    Investing

    5 multi-million dollar takeover targets

    | Motley Fool Staff

    The falling Australian dollar and cheap debt could make Mortgage Choice Limited (ASX:MOC), Treasury Wine Estates Ltd (ASX:TWE), Challenger Ltd…

    Read more »

    a woman
    Investing

    Ham and pineapple could make Anatara Lifesciences Ltd the next CSL Limited 

    | Motley Fool Staff

    Successful trials de-risk the hidden gem that is Anatara Lifesciences Ltd (ASX:ANR).

    Read more »

    a woman
    Investing

    10 stocks up by more than 50% in the past month

    | Mike King

    The market has gone nowhere in the past month, but these 10 stocks are up by more than 50%

    Read more »

    ANR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    10th Mar 2025 2025-03-10T09:23:30 Phase II GaRP-IBS Trial & Anti-Obesity Project UpdatesYesNo9:23am4298k
    7th Mar 2025 2025-03-07T12:33:42 Final Director's Interest NoticeYesNo12:33pm2136k
    7th Mar 2025 2025-03-07T12:33:27 Initial Director's Interest NoticeYesNo12:33pm2136k
    6th Mar 2025 2025-03-06T09:02:50 Trading HaltYesNo9:02am2263k
    28th Feb 2025 2025-02-28T16:42:39 Board ChangesYesNo4:42pm2169k
    25th Feb 2025 2025-02-25T10:58:42 Appendix 4D & Half Year Report 31 December 2024YesNo10:58am25561k
    20th Feb 2025 2025-02-20T11:56:35 Phase II GaRP-IBS Trial & Anti-Obesity Project UpdatesYesNo11:56am3296k
    28th Jan 2025 2025-01-28T10:45:14 Australian Patent Granted for GaRP ProductYesNo10:45am3291k
    15th Jan 2025 2025-01-15T08:24:07 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo8:24am10535k
    24th Dec 2024 2024-12-24T11:42:43 Notification regarding unquoted securities - ANRYesNo11:42am618k

    About Anatara Lifesciences Ltd

    Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in North Melbourne, Australia.

    ANR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    12 Mar 2025 $0.01 $0.00 0.00% 6,204,958 $0.01 $0.01 $0.01
    11 Mar 2025 $0.01 $0.00 0.00% 12,552,317 $0.01 $0.01 $0.01
    10 Mar 2025 $0.01 $-0.03 -76.92% 29,986,217 $0.02 $0.02 $0.01
    05 Mar 2025 $0.04 $-0.01 -22.22% 25,219 $0.05 $0.05 $0.04
    04 Mar 2025 $0.05 $0.00 0.00% 19,197 $0.05 $0.05 $0.05
    03 Mar 2025 $0.04 $0.00 0.00% 24,500 $0.04 $0.04 $0.04
    28 Feb 2025 $0.04 $-0.01 -19.23% 70,000 $0.05 $0.05 $0.04
    27 Feb 2025 $0.05 $0.00 0.00% 30,500 $0.05 $0.05 $0.05
    25 Feb 2025 $0.06 $0.00 0.00% 326,399 $0.06 $0.06 $0.05
    24 Feb 2025 $0.06 $0.00 0.00% 534,532 $0.06 $0.06 $0.06
    21 Feb 2025 $0.06 $0.00 0.00% 20,109 $0.06 $0.06 $0.06
    20 Feb 2025 $0.06 $0.01 23.81% 76,612 $0.04 $0.06 $0.04
    19 Feb 2025 $0.04 $-0.01 -18.18% 679 $0.04 $0.04 $0.04
    17 Feb 2025 $0.06 $0.00 0.00% 54,346 $0.05 $0.06 $0.05
    14 Feb 2025 $0.06 $0.00 0.00% 10,000 $0.06 $0.06 $0.06
    13 Feb 2025 $0.06 $0.00 0.00% 3,307 $0.06 $0.06 $0.06

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Dec 2024 David Brookes Buy 500,000 $25,000
    Participation in share purchase plan.
    23 Dec 2024 John Michailidis Buy 100,000 $5,000
    Participation in share purchase plan.
    18 Nov 2024 John Michailidis Issued 359,640 $20,859
    Issue of securities. 359,640 Performance Rights
    09 Jul 2024 Nicholas Haslam Issued 1,000,000 $40,000
    Issue of options.
    09 Jul 2024 John Michailidis Issued 1,000,000 $40,000
    Issue of options.
    09 Jul 2024 John Michailidis Issued 250,000 $10,000
    Placement.
    09 Jul 2024 David Brookes Issued 1,500,000 $60,000
    Placement.
    09 Jul 2024 David Brookes Issued 2,500,000 $100,000
    Issue of options. As per announcement on 12-07-2024

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr David Lionel Brookes Executive ChairmanExecutive Director Jun 2022
    Dr Brookes has experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as an analyst. Brookes has since held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by Perkin Elmer Inc (NYSE:PKI) in June 2018. He has also Chaired the risk and audit committees in ASX listed companies. He is member of Risk Management Committee.
    Mr Jonathan William Lindh Company SecretaryNon Executive director Nov 2024
    Mr Lindh has 15 years of legal and company secretarial experience. He has worked in private practice for Australian and international law firms, and for a boutique corporate advisory business. Jonathan has experience advising listed and unlisted private and public companies on a range of matters including mergers & acquisitions, divestments, capital raisings, joint ventures, supply/offtake agreements, foreign investment, corporate governance and corporate law issues. Jonathan has also served as company secretary of several ASX listed companies and other private and public companies operating in various industries.
    Mr John Michailidis Chief Operating OfficerExecutive Director Oct 2023
    Mr Michailidis has over 30 years of experience in the healthcare, pharmaceutical and biotechnology industries both in Australia and internationally. He has a record in business transformation, entrepreneurship, translation and commercialisation of science organisations, government engagement and influence, effectiveness in research translation, business development and organisational responsibility
    Simon Erskine Chief Development Director
    -
    John Michailidis Chief Operator Officer
    -
    Michael West Chief Scientific Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    RTL Group Investments Pty Ltd <The Rtl Investment A/C> 22,000,000 11.41%
    Ubs Nominees Pty Ltd 16,642,732 8.63%
    Scintilla Strategic Investments Limited 8,000,000 4.15%
    Himstedt & Co Pty Ltd <The Himstedt Family A/C> 6,900,000 3.58%
    Parma Corporation Pty Ltd 5,576,771 2.89%
    RTL Group Investments Pty Ltd <The Rtl Investment A/C> i 5,000,000 2.59%
    Mr Samuel Francis Hunter 4,862,662 2.52%
    John Dahlsen Superannuation Fund Pty Ltd 4,200,000 2.18%
    Mousetrap Nominees Pty Ltd <Michael Whiting Family A/C> 3,953,053 2.05%
    Mr Michael Andrew Whiting and Mrs Tracey Anne Whiting <Whiting Family S/F A/C> 3,625,000 1.88%
    Myeng Pty Ltd 3,580,211 1.86%
    Calama Holdings Pty Ltd <Mambat Super Fund A/C> 3,371,940 1.75%
    Symington Pty Ltd 3,340,000 1.73%
    Toucan Trading Pty Ltd 3,097,955 1.61%
    Longridge Partners Pty Ltd 2,839,248 1.45%
    Mr Brendan Phyland 2,651,659 1.37%
    Mr Andre Nicholas Marschke and Mrs Shaleah Ann Marschke <Anm S/F A/C> 2,600,000 1.35%
    Octifil Pty Ltd 2,595,416 1.35%
    Tarandi 1996 Pty Ltd <Dr Dl Brookes Super A/C> 2,490,002 1.29%
    Mr David Lionel Brookes and Mrs Elisabeth Mary Brookes <Dahlbrook Family A/C> 2,300,000 1.19%

    Profile

    since

    Note